Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights

t, Poly IC-Poly Arginine

(Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France.

Study results demonstrated Poly-ICR to be a potent vaccine adjuvant

targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that

Poly-ICR, in combination with model antigens, elicits strong anti-

target antibody and CD8 T-cell immune responses. These findings

demonstrate the versatility of Poly-ICR, suggesting that the

compound may possess broad potential for use in both therapeutic and

prophylactic vaccines.

o The company recently announced that it has nominated Hsp 6/11 as a

development candidate targeting the treatment of genital warts (GW)

and recurrent respiratory papillomatosis (RRP), a disease in which

benign tumors grow on the larynx, vocal cords and trachea.

Combined, GW and RRP affect more than 2.5 million people worldwide

and represent an estimated global market potential of more than $1

billion. There are currently no approved cures for either

condition. Early preclinical data suggest that Hsp 6/11 has the

ability to elicit strong T-cell responses against HPV types 6 and 11

target antigens.

"During the quarter, Nventa announced positive clinical results for our lead candidate, HspE7, presented important and compelling findings on the potency of our proprietary adjuvant, and expanded our pipeline by nominating Hsp 6/11 for further development," said Gregory M. McKee, president and chief executive officer at Nventa. "We are also very enthusiastic about our Material Transfer Agreements to leading vaccine developers in the U.S. and abroad who are evaluating Poly-ICR for potential incorporation into a wide range of vaccine products. Nventa remains committed to the value in our core assets and we are working aggressively with multiple parties to explore opportuni

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:7/22/2014)... (PRWEB) July 22, 2014 Quorum Review IRB, ... service for large clinical trials called Quick Step™ . ... designed to address the research industry’s need for seamless study ... service is available for studies planning 50 or more North ... combined planned North American site count of 80 or more. ...
(Date:7/22/2014)... SILVER SPRING, Md. , July 22, 2014 ... ) announced today that it will release its ... on Tuesday, July 29, 2014. United ... July 29, 2014, at 9:00 a.m. Eastern Time.  ... international callers dialing 1-970-315-0533.  A rebroadcast of the ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/22/2014)... Juli 2014 Qforma, ein führender Anbieter ... von Marcus Bergler zum General Manager ... europäischen kommerziellen Aktivitäten von Qforma bereits als Vice ... anschloss, war er in Positionen als VP Vertrieb ... Deutschland bei IMS Health und als Direktor bei ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2
... Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) (,Oncolytics,) reported ... group at The Institute of Cancer Research,London, ... characterizing immune,system responses to administration of intravenous ... paper, entitled "Characterization of the Adaptive and,Innate ...
... 17 OmniSonics Medical,Technologies, Inc., a developer of ... vascular disease, announced today that it has enrolled ... SONIC I is a prospective,multi-centered U.S. registry study ... undergoing percutaneous mechanical,thrombectomy of acute deep vein thrombosis ...
... ANGELES, March 17 Signalife, Inc. (Amex:,SGN - ... several formal,purchase and financial commitments with respect to ... These commitments have,come internationally, including in Japan, other ... Dr. Harmison, the Company,s President and CEO, ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial 2First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System 2Signalife Sees Accretive Purchase and Financial Commitments 2
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
(Date:7/22/2014)... Not much is known about the the genus of ... after a new one was recently discovered in the ... city of Jaen. A description of it appears in ... ). , The new species, Conosimus ... Spanish hemipterologist, for his contributions to the taxonomy of ...
(Date:7/21/2014)... part of a multinational, collaborative effort, researchers from Canada,s ... identify over 100 locations in the human genome associated ... the largest genomic study published on any psychiatric disorder ... , point to biological mechanisms and pathways that may ... treating the disorder, which has seen little innovation in ...
Breaking Biology News(10 mins):Cleveland Clinic researchers discover neuroprotective role of immune cell 2International team sheds new light on biology underlying schizophrenia 2International team sheds new light on biology underlying schizophrenia 3
... brain assigns cells to participate in encoding and storing memories. ... a protein called CREB controls the odds of a neuron ... edition of Science reports the findings, which suggest a new ... other brain injury. , "Making a memory ...
... 2007, issue of the journal Neuron, published by Cell ... numerical information--both abstract quantities and their concrete representations as ... understanding how the brain processes quantitative information as well ... the brain develops in children. Such studies could aid ...
... protein protects human pancreatic cancer cells from being forced ... defenses against out-of-control cell growth, researchers at The University ... the March issue of Molecular Cancer Research. , The ... has been found by researchers at M. D. Anderson ...
Cached Biology News:UCLA/Toronto researchers unlock key to memory storage in brain 2Studies yield insight into the numerical brain 2Studies yield insight into the numerical brain 3Studies yield insight into the numerical brain 4Protein found to shield pancreatic cancer cells from self-destruction 2
... Clone/PAD: ZMD.257. Immunogen: Synthetic peptide derived ... human Connexin 36 protein This peptide ... to generate another Zymed polyclonal Connexin 36 ... with mouse Connexin 36. Reactivity: Mouse ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: